2-氨基-2-氰基-N-甲基乙酰胺 | 50531-01-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-2-氰基-N-甲基乙酰胺
• 英文名称: 2-amino-2-cyano-N-methylacetamide
• CAS: 50531-01-6
• 化学式: C₄H₇N₃O
• mdl: MFCD06657170
• 分子量: 113.119
• InChiKey: BOBATFKNMFWLFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  2-氨基-2-氰基-N-甲基乙酰胺 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 以63%的产率得到2-Diazo-2-cyano-N-methylacetamide
  参考文献：
  名称：

  含重氮和氰基的杂环化合物。1.重氮基乙腈衍生物在5-卤代-1H-1,2,3-三唑类化合物的合成中

  摘要：

  DOI：

  10.1007/bf00506405
• 作为产物：
  描述：

  cyano-hydroxyimino-acetic acid methylamide 在 甲醇 、 aluminium amalgam 作用下， 生成 2-氨基-2-氰基-N-甲基乙酰胺
  参考文献：
  名称：

  Shaw et al., Journal of the Chemical Society, 1959, p. 1648,1652

  摘要：

  DOI：

文献信息

• [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2019243550A1

  公开（公告）日：2019-12-26

  Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

  提供了公式（I）的噻吩衍生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途，如过敏、1型超敏反应或家族性鼻窦炎。
• [EN] 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS<br/>[FR] AMIDES D'ACIDE 4-(5-ISOXAZOLYL OU 5-PYRAZOLYL-1,2,4-OXADIAZOL-3-YL)-MANDÉLIQUE COMME AGONISTES DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE DE TYPE 1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011133734A1

  公开（公告）日：2011-10-27

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物或其立体异构体、盐或前药，其中：Q是，或者R1是苯基，其上取代基为零至3个；而R1、R2、R3、R4、R5和G在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• Intramolecular reactions of enaminonitriles. A new synthesis of .BETA.-aminopyrroles and related heterocycles.
  作者：TADAKAZU MURATA、TOHRU SUGAWARA、KIYOSHI UKAWA

  DOI：10.1248/cpb.26.3080

  日期：——

  Several new β-aminopyrroles, 3-aminoindoles, pyrido [3, 4-b] indoles, and pyrrolo-[3, 2-b] pyridines have been synthesized by a sequence of reactions involving intramolecular addition of an enamine to a cyano group. Enamine (1), prepared from tert-butyl aminocyanoacetate and cyclohexane-1, 3-dione, cyclized after substitution of the methine by ethyl bromoacetate in the presence of sodium ethoxide to afford 2-tert-butoxycarbonyl-2-ethoxycarbonylmethyl-3-imino-4-oxo-4, 5, 6, 7-tetrahydroindoline (2). Reaction of 1 with methyl vinyl ketone-sodium ethoxide furnished 3-amino-2-tert-butoxycarbonyl-4-oxo-4, 5, 6, 7-tetrahydroindole (7). Similarly, certain 3-aminopyrroles (44 and 45) and pyrrolo [3, 2-b] pyridines (51 and 52) have been synthesized from the enamine (41) prepared from acetoacetate and tert-butyl aminocyanoacetate. Enamines (70-72) obtained by condensation of ethyl acetoacetate with aminocyanoacetamides underwent cyclizations to 3-amino-2-carbamoylpyrroles (73-75) upon treatment with base. Several new 3-aminopyrroles thus prepared have been derived into new pyrrolo [3, 2-d]-(78-81) and pyrrolo-[3, 4-d] pyrimidines (90 and 91). A steric effect of the neighbouring butoxycarbonyl group in 41 has also been briefly discussed.

  几种新的β-氨基吡咯、3-氨基吲哚、吡啶[3, 4-b]吲哚和吡咯啉[3, 2-b]吡啶通过一系列反应合成，涉及到烯胺与氰基的分子内加成反应。烯胺（1）是由叔丁基氨基氰乙酸酯和环己烯-1，3-二酮制备的，在存在乙醇钠的条件下，经过乙基溴乙酸酯取代甲烯后环化，得到2-叔丁氧羰基-2-乙氧羰基甲基-3-亚氨基-4-氧基-4, 5, 6, 7-四氢吲哚（2）。烯胺1与乙烯基甲酮-乙醇钠反应生成3-氨基-2-叔丁氧羰基-4-氧基-4, 5, 6, 7-四氢吲哚（7）。类似地，某些3-氨基吡咯（44和45）和吡咯啉[3, 2-b]吡啶（51和52）也是通过与叔丁基氨基氰乙酸酯反应得到的烯胺（41）合成的。通过将乙基乙酰乙酸酯与氨基氰乙酰酰胺缩合得到的烯胺（70-72）在碱的处理下经历环化反应，形成3-氨基-2-氨甲酰吡咯（73-75）。因此，几种新制备的3-氨基吡咯进一步衍生为新的吡咯啉[3, 2-d]（78-81）和吡咯啉-[3, 4-d]嘧啶（90和91）。文中还简要讨论了邻近的丁氧羰基在41中的空间效应。
• MANDELAMIDE HETEROCYCLIC COMPOUNDS
  申请人：Cherney Robert J.

  公开号：US20130045964A1

  公开（公告）日：2013-02-21

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R 1 is phenyl substituted with zero to 3 substituents; and R 1 , R 2 , R 3 , R 4 , R 5 , and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）的化合物或其立体异构体、盐或前药，其中：Q是，或R1是带有零到3个取代基的苯基；R1、R2、R3、R4、R5和G在此处被定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展中有用，例如自身免疫性疾病和血管疾病。
• Mandelamide heterocyclic compounds
  申请人：Cherney Robert J.

  公开号：US08835470B2

  公开（公告）日：2014-09-16

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）的化合物或其立体异构体、盐或前药，其中：Q为，或R1为带有0至3个取代基的苯基；R1、R2、R3、R4、R5和G在此定义。本发明还涉及使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的制药组合物。这些化合物可用于治疗、预防或减缓多种治疗领域的疾病或障碍，例如自身免疫性疾病和血管疾病。